Release Date: 09/03/12 08:26 Summary: Becoming a substantial holder in MMX by DB Group-Schedule 3 Price Sensitive: No Download Document 7.54MB Download
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling